Seaweed biotech disrupting the billion-dollar supplement market

PhycoLife (Venus Shell Systems P/L)

Register your interest

By registering your interest, you consent to the Company receiving your contact details for the purposes of this offer.

Unsustainable Sourcing: Seaweed Innovation Creating a New Market

The global demand for health supplements is booming, with the chondroitin sulfate ingredient alone valued at over $1.7 billion USD in a $7.8 billion supplement market, and projected to grow. However, a troubling truth underpins the chondroitin industry: it is sources from animal bones but 40% is sourced from shark cartilage due to its high chondroitin concentration compared to bovine or synthetic alternatives. This practice sees millions of wild sharks like Blue Sharks and Hammer Heads harvested annually, devastating marine ecosystems and alarming ethically-conscious consumers worldwide.

This critical issue creates a significant market opening. PhycoLife is strategically positioned with a scientifically validated, sustainably farmed seaweed alternative, delivering the important molecular structure found in shark cartilage without ecological devastation.

As consumer demand for ethical, plant-based solutions intensifies, PhycoLife has a clear pathway to capture a substantial share of this expanding multi-billion dollar market, offering potent innovations that heal people and our planet.

We are turning an environmental crisis into a frontier for biotech investment.

 

High-Growth, High-Impact Investment Opportunity

By Investing in PhycoLife, you're investing in a revenue-generating seaweed biotech leader disrupting a >$7.5B global supplements market.

  • Scaled, proven and de-risked model: our traction means we are in a position to lead Australia's rapidly expanding blue bio-economy, benefiting both human health and our oceans.
  • Huge Market Disruption: Targeting the >$1.7B global chondroitin market, replacing unsustainable shark cartilage (currently 30-40% source) with our unique, clinically proven seaweed alternative.
  • Rapid Revenue Growth & Loyalty: $1M+ revenue (FY25), fuelled by 160% sales growth (revenue tripled in 6 months) and exceptional ~60% customer retention, demonstrating strong market demand.
  • Pioneering De-risked Model: Australia’s first fully integrated seaweed biotech—from innovative indoor farming and bio-refining to proven medical and food-grade finished products.
  • Proprietary & Clinically Validated: Proprietary seaweed ingredients (e.g., Phyaluronic™) backed by two human clinical trials showing significant gut health, cholesterol, and anti-inflammatory benefits.
  • Scaling for Global Impact & NSW Leadership: Investment can potentially 10x production for global D2C/B2B reach, spearheading NSW’s visionary $2.3B seaweed economy.

Integrated Innovation, Creation, and Control

Building on our proven model highlighted previously, PhycoLife's core strength lies in our comprehensive mastery of the entire seaweed value chain. We are not simply product sellers; we are fundamental creators, meticulously managing every stage from proprietary indoor marine cultivation and advanced bio-refining to the formulation of market-leading health products that meet stringent food and medical standards.

This end-to-end Australian-based supply chain control is crucial for our innovation, ensuring premium quality, traceability, and the rapid development of novel solutions.

Our commitment extends deeply into pioneering research and development. PhycoLife functions as a deep-tech innovation engine, actively driving glycobiology and marine biotechnology advancements that could lead to opportunities beyond what the market can see.

This R&D focus generates significant intellectual property, which underpins our unique ingredients like Phyaluronic™ (SXRG84) and our next-generation SeaFibre supplements. This integrated system of sustainable cultivation, controlled processing, and frontier science allows us to consistently deliver our diverse range of clinically validated supplements, bioactive skincare, and award-winning functional foods to a discerning market.

Join the $2.3 billion NSW Seaweed Economy Vision

PhycoLife is strategically positioned within a rapidly expanding wellness landscape. Our initial targeted disruption is the ~$1.5 billion global shark cartilage supplement market (projected ~8.2% CAGR), offering a scientifically validated, ethical alternative to an ingredient that currently supplies 30-40% of the broader >$7.5 billion chondroitin sulfate supplements market. This precise entry point is just the beginning.

The global demand for sustainable, plant-based, and clinically proven health solutions is accelerating, creating enormous uplift. This trend directly fuels our international scaling strategy, particularly for the B2B supply of our proprietary seaweed ingredients to global nutraceutical, food and medical brands. Furthermore, our ongoing R&D in marine glycobiology continually unlocks significant growth opportunities across functional foods, advanced skincare, and new therapeutic applications.

PhycoLife is not just meeting current demand; we are building an innovation platform to lead within Australia's $2.3 billion NSW seaweed economy vision and the multitrillion dollar global wellness industry. NSW is well poised for real estate and resources to support this growth.

$1m in Revenue FY25 + 60% Customer Retention

PhycoLife has achieved significant milestones, validating our business model and strong market demand. We proudly surpassed $1 million in revenue in FY25, driven by 160% annual sales growth and revenue tripling in the last six months alone. Our product efficacy and brand loyalty are confirmed by an exceptional ~60% customer retention rate and a customer base that more than doubled in the past year.

Operationally, we pioneered Australia’s first fully integrated seaweed value chain—from proprietary indoor cultivation and biorefining to creating novel ingredients like Phyaluronic™ that are clinically tested and that meet food grade standards. Our science is robust, with two pioneering human clinical trials published, leading to strong research partnerships across 4 universities and with numerous industry partners. This innovation and market leadership have garnered significant industry recognition, including multiple Australian Food Awards, "Most Innovative Protein Source" (International Food Expo London 2025), and prominent features in Forbes, BBC, and ABC.

These accomplishments showcase a de-risked, revenue-generating business primed for accelerated scaling.

Our Unique Advantage: Integrated Science, IP & Proof

PhycoLife’s competitive advantage is multi-layered and deeply entrenched, built on being Australia's pioneering, fully integrated seaweed biotech company.

Replicating our model is a formidable challenge due to the significant investment and specialised expertise required to master the entire value chain—from proprietary indoor cultivation and advanced bio-refining in Australia to creating medical-grade ingredients. This end-to-end sovereign control ensures unparalleled quality, traceability, and rapid innovation.

Crucially, we are an IP-generating, science-first company. Our deep expertise in marine glycobiology fuels a growing portfolio of proprietary ingredients like Phyaluronic™ and now Phychondrin™ . Our solutions are validated by two human clinical trials—a level of rigorous scientific backing rarely seen in this market.

This powerful fusion of a de-risked, scalable Australian supply chain, protected intellectual property, and proven product efficacy allows us to create truly unique, high-value offerings. Investors are backing a category leader with substantial barriers to entry, perfectly positioned to define the future where sustainable biotech meets scientifically proven health.

Investor rewards

We want our shareholders to be as big fans of our products as we are, and to reap the health rewards. We are proud off offer a range of rewards for investment in the crowd equity campaign as follows:

 

Our Team

Pia Winberg

Founder & CEO

A highly cited marine-systems and molecular ecologist turned entrepreneur. Pia is a visionary technology leader in seaweed and marine food production, renowned for connecting natural systems to market solutions and driving change through action, regularly featured on global media.

Anthony Hargreaves

Director

With over 15 years in corporate advisory, Anthony specialises in capital raises and ASX listings, having helped secure over A$300 million for Australian corporations and overseen approximately 12 IPOs. He brings extensive financial growth expertise to PhycoLife.

John Kelly

Director

John offers extensive product development experience from major medical device companies (e.g., ResMed) and startups. As Founder/CEO of Atomo Diagnostics, he provides invaluable insights into operational chains and technology-driven business growth strategies.

 

Always consider the general CSF risk-warning and offer document before investing

Please note: Investments over $10,000 are restricted to Sophisticated investors - Apply here

Want to know more about equity crowdfunding? Click here

Register your interest

Discover investment opportunities here.

 

CSF Register for early access

PhycoLife (Venus Shell Systems P/L)

Seaweed biotech disrupting the billion-dollar supplement market

 

PhycoLife is revolutionising health with sustainable seaweed solutions. With $1m+ in revenue in FY25 and strong customer loyalty, they're raising capital to scale their clinically proven, plantbased alternative to bone and shark cartilage supplements, targeting the $7.5B market. 

Wholesale Bidding Closed

Recludo Ltd

Consolidating the $356bn Australian mortgage broker industry

 

Recludo Ltd is consolidating the Australian mortgage broker industry by selectively investing in the top 5% of mortgage broker businesses. With over 22,000 independent mortgage brokers writing 75% of all new home loans, representing a $356 billion annual market opportunity, it is a highly fragmented market ripe for consolidation. Recludo has the team, the experience and the network to be a first mover in this significant market opportunity.

$0.125Price
Up to $10 millionSize of Offer
05 May 25Offer Open
01 Jun 25Pay By
CSF Closed Mar 2025

Prohibition Liquor Co. Ltd

The Prohibition Liquor Co. Ltd CSF offer has closed successfully. Prohibition has grown into one of Australia’s most awarded and respected distilleries, earning hundreds of international accolades. They are now embarking on an exciting new chapter—expanding to the historic Seppeltsfield Distillery in the Barossa Valley

Fully Funded

$2.6 million

Raised

1,128

Investors